3Jaruratanasirikul S,Limapichat T,Jullangkoon M,et al.Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia[J].Int J Antimicrob Agents,2011,38(3):231-236.
4Gilbert DN,Moellering RC,Eliopoulos GM.The Sanford guide to antimicrobial therapy[M].43rd.Antimicrobial Therapy,2013:110-111.
6Falagas ME,Tansarli GS,Ikawa K,et al.Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam:a systematic review and meta-analysis[J].Clin Infect Dis,2013,56(2):272-282.
4Gaynes R,Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli[J].{H}Clinical Infectious Diseases,2005.848-854.
5Neuhauser MM,Weinstein RA,Rydman R. Antibiotic resistance among gram-negative bacilli in US intensive care units:implications for fluoroquinolone use[J].{H}JAMA:the Journal of the American Medical Association,2003.885-888.
6Fujitani S,Sun HY,Yu VL. Pneumonia due to Pseudomonas aeruginosa:part Ⅰ:epidemiology,clinical diagnosis,and source[J].{H}CHEST,2011.909-919.
7Fine MJ,Smith MA,Carson CA. Prognosis and outcomes of patients with community-acquired pneumonia.A meta-analysis[J].{H}JAMA:the Journal of the American Medical Association,1996.134-141.
8Parameswaran GI,Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease[J].Future Microbiol,2012.1129-1132.
9Robert A,Bonomo RA,Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa[J].{H}Clinical Infectious Diseases,2006,(Suppl 2):S49-S56.
10Woodhead M,Blasi F,Ewig S. Guidelines for the management of adult lower respiratory tract infections--full version[J].{H}Clinical Microbiology and Infection,2011,(Suppl 6):El-59.
